The COPD therapy, administered using the ELLIPTA inhaler, is a combination of GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA).
The regulatory application was submitted to the European Union for the investigational once-daily UMEC/VI combination therapy of 55/22mcg and 113/22mcg doses as a maintenance bronchodilator treatment to relieve symptoms in COPD patients.
Companies previously submitted a regulatory application for UMEC/VI in the US for COPD patients.